

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	33.5	80.7	(53.2-117.4)	Male	19	20.4	93.3	(56.1-145.6)
Female	8	11.3	70.8	(30.5-139.6)	Female	11	15.0	73.2	(36.5-131.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	88.5	(28.5-206.4)	Male	6	6.5	92.5	(33.8-201.2)
Female	5	4.9	102.4	(33.0-238.9)	Female	4	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	17.9	134.0	(85.8-199.3)
Female	131	123.6	105.9	(88.6-125.7)	Female	13	15.1	85.9	(45.7-146.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-135.0)
<u>Colon / Rectum</u>					Female	5	6.7	74.8	(24.1-174.6)
Male	27	33.1	81.7	(53.8-118.8)	<u>Ovary</u>				
Female	30	31.4	95.6	(64.5-136.5)	Female	9	10.5	85.6	(39.1-162.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	7.7	nc	(nc-nc)	Male	19	11.7	161.8	(97.3-252.6)
Female	1	2.2	nc	(nc-nc)	Female	7	11.7	60.0	(24.0-123.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	75	83.9	89.4	(70.3-112.0)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.5	79.9	(29.2-174.0)
Male	16	16.9	94.6	(54.1-153.7)	Female	3	4.4	nc	(nc-nc)
Female	5	10.0	49.9	(16.1-116.6)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.9	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	8	7.3	110.3	(47.5-217.4)
<u>Leukemia</u>					Female	31	22.0	141.0	(95.8-200.2)
Male	16	12.8	125.1	(71.5-203.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.8	56.7	(18.3-132.4)	Female	34	27.6	123.1	(85.2-172.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.5	76.4	(32.9-150.6)	Male	352	390.9	90.0	(80.9-100.0)
Female	3	3.6	nc	(nc-nc)	Female	395	415.1	95.2	(86.0-105.0)
<u>Lung and Bronchus</u>									
Male	39	56.9	68.6	(48.8-93.8)					
Female	60	61.1	98.3	(75.0-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;